This clinical trial is designed to investigate a new treatment option for patients with advanced solid tumors, which are a type of cancer that has spread and is not easily treated. The study focuses on a new drug named YL242 and aims to understand how safe and tolerable it is when used alone or in combination with other treatments. Patients with these advanced tumors often have limited treatment options, so this study is important because it may lead to new ways to manage their condition effectively. Participants in this study will receive YL242, either on its own or alongside other therapies, and their health will be closely monitored. The treatment is administered in a controlled setting, and researchers will evaluate how the drug behaves in the body and its effects on the tumors. The main focus is to see if the treatment is safe and how well it is tolerated by patients. Through regular health assessments, the study aims to gather comprehensive information on the potential benefits and any possible side effects of YL242, contributing to the development of better cancer treatments.
Inclusion Criteria: * Aged ≥18 years. * Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 * Adequate organ and bone marrow function * Tumor type: Part 1-3: Advanced/unresectable or metastatic solid malignant tumor; Have received at least one prior line of systemic anti-tumor therapy Part 4: locally advanced or metastatic non-sq NSCLC without AGA and HCC; Have not received any systemic anti-tumor therapy; Part 5: mCRC, have received at least one (5a) or one (5b) prior line of systemic anti-tumor therapy Part 6: advanced or metastatic HER2-negative G/GEJ; have received at least one (6a) or one (6b) prior line of systemic anti-tumor therapy Exclusion Criteria: * Be intolerant to prior treatment with a topoisomerase I inhibitor or an ADC that consists of a topoisomerase I inhibitor * Uncontrolled or clinically significant cardiovascular and cerebrovascular diseases * Clinically significant concomitant pulmonary disease * A history of leptomeningeal carcinomatosis or carcinomatous meningitis * Any illness, medical condition, organ system dysfunction, or social situation, including but not limited to mental illness or substance/alcohol abuse, deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, adversely affect the patient's ability to cooperate and participate in the study, or compromise the interpretation of study results
are designated in this study